Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Phase 2 Trial of 177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With High-Risk Castrate Biochemically Relapsed Prostate Cancer After Local Therapy

Next Previous
Trial Profile

A Randomized Phase 2 Trial of 177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With High-Risk Castrate Biochemically Relapsed Prostate Cancer After Local Therapy

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 08 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ATL 101 Telix Pharmaceuticals (Primary) ; Hydrocortisone; J 591-radiolabelled; Ketoconazole
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Therapeutic Use

Most Recent Events

  • 30 Apr 2025 Planned End Date changed from 1 Dec 2025 to 1 May 2026.
  • 18 Feb 2023 Results assessing that 177Lu prolongs 18-month (mo) met-free survival (MFS) more than 111In in patients with high-risk non-metastatic castration-resistant prostate cancer, presented at the 2023 Genitourinary Cancers Symposium
  • 18 Feb 2023 Results assessing 177Lu prolongs 18-month (mo) met-free survival (MFS) more than 111In in pts with high risk, M0 CRPC when targeting PSMA via J591 in combo with keto and HC presented at the 2023 Genitourinary Cancers Symposium

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top